Summary
This 8-K filing from Medtronic plc details the outcomes of its 2022 Annual General Meeting of Shareholders held on December 8, 2022. The meeting served as a platform for shareholders to vote on key corporate governance matters, including the election of directors, ratification of the independent auditor, executive compensation, and authorities related to share issuance and repurchases. The overall results indicate strong shareholder support for the company's management and proposed actions. Key proposals, including the election of all eleven director nominees and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023, received overwhelming approval. Shareholder approval was also granted for the compensation of named executive officers and for renewing the Board's authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of Medtronic ordinary shares. The significant turnout and affirmative votes demonstrate shareholder confidence in Medtronic's leadership and strategic direction.
Key Highlights
- 1All eleven director nominees were overwhelmingly elected to serve until the 2023 Annual General Meeting.
- 2PricewaterhouseCoopers LLP was ratified as Medtronic's independent auditor for fiscal year 2023 with strong shareholder support.
- 3Shareholders approved, on a non-binding advisory basis, the compensation awarded to the company's named executive officers.
- 4The Board's authority to issue shares was renewed by shareholder approval.
- 5Shareholders approved the renewal of the Board's authority to opt out of pre-emption rights.
- 6Authorization for Medtronic and its subsidiaries to make overseas market purchases of Medtronic ordinary shares was approved by shareholders.
- 7A quorum was established with holders of over a majority of the outstanding ordinary shares entitled to vote present at the meeting.